T2Bacteria® Panel
The first and only in-vitro diagnostic test to receive approval for a New Technology Add-On Payment (NTAP) by CMS
LEARN MORE

"The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections."

– US CMS FY 2020 inpatient prospective payments system final rule
T2Bacteria® Panel
The first and only in-vitro diagnostic test to receive approval for a New Technology Add-On Payment (NTAP) by CMS
LEARN MORE

"The T2Bacteria Test Panel represents a substantial clinical improvement over existing technologies because it reduces the proportion of patients on inappropriate therapy, thus reducing the rate of subsequent diagnostic or therapeutic intervention as well as length of stay and mortality rates caused by sepsis causing bacterial infections."

– US CMS FY 2020 inpatient prospective payments system final rule

T2 could save lives – bottomline.

Now, hospitals can detect and identify sepsis-causing pathogens faster and more accurately.

Hospitals trust in T2 technology.

Gregorio Marañón Hospital in Madrid, Spain
Two 2018 studies from Gregorio Marañón Hospital in Madrid, Spain.
Rigshospitalet, Denmark
"T2Candida was superior to blood culture and mannan antigen and may improve diagnosis."
Gemelli Hospital, Italy
66.7% of the clinically infected patients missed by blood culture were correctly identified by T2Bacteria
La Paz Hospital University, Spain
T2Candia Panel contributed to the healthy discharge of a 1-year-old transplant patient.

Patient Case Studies

Real stories about how T2 Biosystems™ could have potentially changed clinical practice and patient outcomes.

Secondary Candidemia in Critically Ill COVID-19 Patient

T2Candida enabled the detection of candidemia 29 hours before a positive blood culture was returned. Early detection allowed for the rapid initiation of antifungal therapy in a critically ill COVID-19 patient.

Case Study 1

53-year-old immunocompromised, female with recent surgery to drain an intra-abdominal abscess

Case Study 2

25-year-old female with cerebral palsy diagnosed with duodenal pneumatosis

Case Study 3

73-year-old female with lymphoma on chemotherapy and diagnosed with pneumonia and septic shock
Previous
Next

Numbers don't lie.

Mortality increases

8%
each hour of delayed treatment

Sepsis kills

~6 million
people worldwide annually.

Sepsis impacts

30 million
people worldwide each year.
Integrate T2Direct Diagnostics into your hospital today!

Stewardship Case Studies